beta-Myrcene: Target Organs and Levels of Evidence for TR-557
Toxicology and Carcinogenesis Studies of beta-Myrcene (CASRN 123-35-3) in F344/N Rats and B6C3F1 Mice (Gavage Studies)
Chemical (Study Title)
CASRN | Peer Review Date | Route/Exposure Levels | Study Laboratory |
|---|
beta-Myrcene
123-35-3 | 02/25/2009 | Gavage
R&M: 0, 0.25, 0.5, OR 1.0 G/KG; 50/SEX/DOSE | Battelle Columbus Laboratory |
Levels of Evidence
Male Rats: Clear Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Kidney Tubular Cell:
Adenoma (standard evaluation) 0/50 4/50 8/50 (standard and extended evaluations) 0/50 12/50 13/50 adenoma or carcinoma (standard evaluation) 0/50 7/50 9/50 (standard and extended evaluations) 0/50 14/50 13/50
|
| Non-Neoplastic Lesions | - Kidney: renal tubule, nephrosis; papilla, mineralization; severity of nephropathy; transitional epithelium, hyperplasia; inflammation, suppurative, focal
- Nose: inflammation, chronic active
|
Female Rats: Equivocal Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| May Have Been Related | - Kidney Tubular Cell:
Adenoma (standard evaluation) 0/50 1/50 0/50 2/50 extended evaluation 0/50 1/50 1/50 2/50 standard and extended evaluations 0/50 2/50 1/50 3/50
|
| Non-Neoplastic Lesions | - Kidney: renal tubule, nephrosis; nephropathy; severity of nephropathy; transitional epithelium, hyperplasia
|
Male Mice: Clear Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| Neoplastic Lesions | - Liver:
Adenoma 26/50 41/50 43/50 carcinoma 14/50 20/50 28/50 adenoma or carcinoma 33/50 44/50 48/50 hepatoblastoma 4/50 6/50 11/50 adenoma, carcinoma, or hepatoblastoma 34/50 45/50 48/50
|
| Non-Neoplastic Lesions | - Liver: Hepatocyte, hypertrophy
|
Female Mice: Equivocal Evidence
| Type | Organ/Tissue (Lesion) |
|---|
| May Have Been Related | - Liver:
Adenoma 6/50 13/50 6/50 carcinoma 1/50 7/50 2/50 adenoma or carcinoma 7/50 18/50 8/50
|
| Non-Neoplastic Lesions | - Liver: Hepatocyte, hypertrophy; mixed cell focus
|
